Filing Flows › Comparisons › EVMN vs INBP
Evommune vs Integrated Biopharma: EVMN and INBP compared
Evommune is the larger company: $10.0M of revenue in its latest quarter (Q3 2025) against $9.8M for Integrated Biopharma (Q4 FY26). Integrated Biopharma is more profitable, with an operating margin of -8.9% against -133.3%.
Where the money goes: EVMN and INBP
Evommune (EVMN) · Q3 2025
Evommune, Q3 2025: revenue $10.0M, operating margin -133.3%, net loss $12.5M, operating cash flow −$9.6M. The chart follows the revenue to costs, profit and cash.
Integrated Biopharma (INBP) · Q4 FY26
Integrated Biopharma, Q4 FY26: revenue $9.8M (-31% year over year), operating margin -8.9%, net loss $1.4M, operating cash flow −$1.2M. The chart follows the revenue to costs, profit and cash.
| Evommune (EVMN) | Integrated Biopharma (INBP) | |
|---|---|---|
| Latest quarter | Q3 2025 | Q4 FY26 |
| Revenue | $10.0M | $9.8M |
| Revenue growth, Y/Y | — | -31% |
| Operating margin | -133.3% | -8.9% |
| Net earnings | −$12.5M | −$1.4M |
| Net margin | -124.8% | -13.9% |
| Operating cash flow | −$9.6M | −$1.2M |
Where the revenue comes from
Integrated Biopharma
- Contract Manufacturing: $9.5M (97%)
- Other Nutraceutical Business: $318K (3%)
Questions
Which is bigger, Evommune or Integrated Biopharma?
Evommune is the larger company: $10.0M of revenue in its latest quarter (Q3 2025) against $9.8M for Integrated Biopharma (Q4 FY26).
Is Evommune or Integrated Biopharma growing faster?
Integrated Biopharma is more profitable, with an operating margin of -8.9% against -133.3%.
More: Evommune earnings · how Evommune makes money · Integrated Biopharma earnings · how Integrated Biopharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Dec 11, 2025; 10-K filed Sep 25, 2026). Fiscal quarters can end on different dates. Not investment advice.